BMB Reports

Korean Society for Biochemistry and Molecular Biology (생화학분자생물학회)
권호 표지
DOI QR코드

DOI QR Code

Degradation or aggregation: the ramifications of post-translational modifications on tau

  • Park, Seoyoung (Department of Biochemistry and Molecular Biology, Seoul National University College of Medicine) ;
  • Lee, Jung Hoon (Department of Biochemistry and Molecular Biology, Seoul National University College of Medicine) ;
  • Jeon, Jun Hyoung (Department of Biochemistry and Molecular Biology, Seoul National University College of Medicine) ;
  • Lee, Min Jae (Department of Biochemistry and Molecular Biology, Seoul National University College of Medicine)
  • Received : 2018.04.11
  • Published : 2018.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

Tau protein is encoded in the microtubule-associated protein tau (MAPT) gene and contributes to the stability of microtubules in axons. Despite of its basic isoelectric point and high solubility, tau is often found in intraneuronal filamentous inclusions such as paired helical filaments (PHFs), which are the primary constituent of neurofibrillary tangles (NFTs). This pathological feature is the nosological entity termed "tauopathies" which notably include Alzheimer's disease (AD). A proteinaceous signature of all tauopathies is hyperphosphorylation of the accumulated tau, which has been extensively studied as a major pharmacological target for AD therapy. However, in addition to phosphorylation events, tau undergoes a number of diverse posttranslational modifications (PTMs) which appear to be controlled by complex crosstalk. It remains to be elucidated which of the PTMs or their combinations have pro-aggregation or anti-aggregation properties. In this review, we outline the consequences of and communications between several key PTMs of tau, such as acetylation, phosphorylation, and ubiquitination, focusing on their roles in aggregation and degradation. We place emphasis on the structure of tau protofilaments from the human AD brain, which may be good targets to modulate etiological PTMs which cause tau aggregation.

Keywords

References

  1. Mandelkow EM and Mandelkow E (1998) Tau in Alzheimer's disease. Trends Cell Biol 8, 425-427 https://doi.org/10.1016/S0962-8924(98)01368-3
  2. Andreadis A (2006) Misregulation of tau alternative splicing in neurodegeneration and dementia. Prog Mol Subcell Biol 44, 89-107
  3. Goedert M, Spillantini MG, Jakes R, Rutherford D and Crowther RA (1989) Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer's disease. Neuron 3, 519-526 https://doi.org/10.1016/0896-6273(89)90210-9
  4. Goedert M, Cohen ES, Jakes R and Cohen P (1992) p42 MAP kinase phosphorylation sites in microtubule-associated protein tau are dephosphorylated by protein phosphatase 2A1. Implications for Alzheimer's disease [corrected]. FEBS Lett 312, 95-99 https://doi.org/10.1016/0014-5793(92)81418-L
  5. Kyte J and Doolittle RF (1982) A simple method for displaying the hydropathic character of a protein. J Mol Biol 157, 105-132 https://doi.org/10.1016/0022-2836(82)90515-0
  6. Alonso AD, Zaidi T, Novak M, Barra HS, Grundke-Iqbal I and Iqbal K (2001) Interaction of tau isoforms with Alzheimer's disease abnormally hyperphosphorylated tau and in vitro phosphorylation into the disease-like protein. J Biol Chem 276, 37967-37973
  7. Wolfe MS (2009) Tau mutations in neurodegenerative diseases. J Biol Chem 284, 6021-6025 https://doi.org/10.1074/jbc.R800013200
  8. Abraha A, Ghoshal N, Gamblin TC et al (2000) C-terminal inhibition of tau assembly in vitro and in Alzheimer's disease. J Cell Sci 113 Pt 21, 3737-3745
  9. Flores-Rodriguez P, Ontiveros-Torres MA, Cardenas-Aguayo MC et al (2015) The relationship between truncation and phosphorylation at the C-terminus of tau protein in the paired helical filaments of Alzheimer's disease. Front Neurosci 9, 33
  10. Peeraer E, Bottelbergs A, Van Kolen K et al (2015) Intracerebral injection of preformed synthetic tau fibrils initiates widespread tauopathy and neuronal loss in the brains of tau transgenic mice. Neurobiol Dis 73, 83-95 https://doi.org/10.1016/j.nbd.2014.08.032
  11. Guo JL and Lee VM (2013) Neurofibrillary tangle-like tau pathology induced by synthetic tau fibrils in primary neurons over-expressing mutant tau. FEBS Lett 587, 717-723 https://doi.org/10.1016/j.febslet.2013.01.051
  12. Guo JL and Lee VM (2011) Seeding of normal Tau by pathological Tau conformers drives pathogenesis of Alzheimer-like tangles. J Biol Chem 286, 15317-15331 https://doi.org/10.1074/jbc.M110.209296
  13. Nubling G, Bader B, Levin J, Hildebrandt J, Kretzschmar H and Giese A (2012) Synergistic influence of phosphorylation and metal ions on tau oligomer formation and coaggregation with alpha-synuclein at the single molecule level. Mol Neurodegener 7, 35 https://doi.org/10.1186/1750-1326-7-35
  14. Choi TS, Lee J, Han JY et al (2018) Supramolecular Modulation of Structural Polymorphism in Pathogenic alpha-Synuclein Fibrils Using Copper(II) Coordination. Angew Chem Int Ed Engl 57, 3099-3103 https://doi.org/10.1002/anie.201712286
  15. Wille H, Drewes G, Biernat J, Mandelkow EM and Mandelkow E (1992) Alzheimer-like paired helical filaments and antiparallel dimers formed from microtubule-associated protein tau in vitro. J Cell Biol 118, 573-584 https://doi.org/10.1083/jcb.118.3.573
  16. Fitzpatrick AWP, Falcon B, He S et al (2017) Cryo-EM structures of tau filaments from Alzheimer's disease. Nature 547, 185-190 https://doi.org/10.1038/nature23002
  17. Giannakopoulos P, Herrmann FR, Bussiere T et al (2003) Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer's disease. Neurology 60, 1495-1500 https://doi.org/10.1212/01.WNL.0000063311.58879.01
  18. Ethell DW (2010) An amyloid-notch hypothesis for Alzheimer's disease. Neuroscientist 16, 614-617 https://doi.org/10.1177/1073858410366162
  19. Hung SY and Fu WM (2017) Drug candidates in clinical trials for Alzheimer's disease. J Biomed Sci 24, 47 https://doi.org/10.1186/s12929-017-0355-7
  20. Wang Y and Mandelkow E (2016) Tau in physiology and pathology. Nat Rev Neurosci 17, 5-21 https://doi.org/10.1038/nrg.2015.11
  21. Min SW, Cho SH, Zhou Y et al (2010) Acetylation of tau inhibits its degradation and contributes to tauopathy. Neuron 67, 953-966 https://doi.org/10.1016/j.neuron.2010.08.044
  22. Roth SY, Denu JM and Allis CD (2001) Histone acetyltransferases. Annu Rev Biochem 70, 81-120 https://doi.org/10.1146/annurev.biochem.70.1.81
  23. Liu X, Wang L, Zhao K et al (2008) The structural basis of protein acetylation by the p300/CBP transcriptional coactivator. Nature 451, 846-850 https://doi.org/10.1038/nature06546
  24. Marmorstein R (2001) Structure of histone acetyltransferases. J Mol Biol 311, 433-444 https://doi.org/10.1006/jmbi.2001.4859
  25. Cohen TJ, Guo JL, Hurtado DE et al (2011) The acetylation of tau inhibits its function and promotes pathological tau aggregation. Nat Commun 2, 252 https://doi.org/10.1038/ncomms1255
  26. Morris M, Knudsen GM, Maeda S et al (2015) Tau post-translational modifications in wild-type and human amyloid precursor protein transgenic mice. Nat Neurosci 18, 1183-1189 https://doi.org/10.1038/nn.4067
  27. Cook C, Carlomagno Y, Gendron TF et al (2014) Acetylation of the KXGS motifs in tau is a critical determinant in modulation of tau aggregation and clearance. Hum Mol Genet 23, 104-116 https://doi.org/10.1093/hmg/ddt402
  28. Ding H, Dolan PJ and Johnson GV (2008) Histone deacetylase 6 interacts with the microtubule-associated protein tau. J Neurochem 106, 2119-2130 https://doi.org/10.1111/j.1471-4159.2008.05564.x
  29. Fan SJ, Huang FI, Liou JP, Yang CR (2018) The novel histone de acetylase 6 inhibitor, MPT0G211, ameliorates tau phosphorylation and cognitive deficits in an Alzheimer's disease model. Cell Death Dis 9, 655 https://doi.org/10.1038/s41419-018-0688-5
  30. Carlomagno Y, Chung DC, Yue M et al (2017) An acetylation-phosphorylation switch that regulates tau aggregation propensity and function. J Biol Chem 292, 15277-15286 https://doi.org/10.1074/jbc.M117.794602
  31. Julien C, Tremblay C, Emond V et al (2009) Sirtuin 1 reduction parallels the accumulation of tau in Alzheimer disease. J Neuropathol Exp Neurol 68, 48-58 https://doi.org/10.1097/NEN.0b013e3181922348
  32. Gorsky MK, Burnouf S, Sofola-Adesakin O et al (2017) Pseudo-acetylation of multiple sites on human Tau proteins alters Tau phosphorylation and microtubule binding, and ameliorates amyloid beta toxicity. Sci Rep 7, 9984 https://doi.org/10.1038/s41598-017-10225-0
  33. Min SW, Chen X, Tracy TE et al (2015) Critical role of acetylation in tau-mediated neurodegeneration and cognitive deficits. Nat Med 21, 1154-1162 https://doi.org/10.1038/nm.3951
  34. Tracy TE, Sohn PD, Minami SS et al (2016) Acetylated Tau Obstructs KIBRA-Mediated Signaling in Synaptic Plasticity and Promotes Tauopathy-Related Memory Loss. Neuron 90, 245-260 https://doi.org/10.1016/j.neuron.2016.03.005
  35. Irwin DJ, Cohen TJ, Grossman M et al (2013) Acetylated tau neuropathology in sporadic and hereditary tauopathies. Am J Pathol 183, 344-351 https://doi.org/10.1016/j.ajpath.2013.04.025
  36. Trzeciakiewicz H, Tseng JH, Wander CM et al (2017) A Dual Pathogenic Mechanism Links Tau Acetylation to Sporadic Tauopathy. Sci Rep 7, 44102 https://doi.org/10.1038/srep44102
  37. Gorsky MK, Burnouf S, Dols J, Mandelkow E and Partridge L (2016) Acetylation mimic of lysine 280 exacerbates human Tau neurotoxicity in vivo. Sci Rep 6, 22685 https://doi.org/10.1038/srep22685
  38. Irwin DJ, Cohen TJ, Grossman M et al (2012) Acetylated tau, a novel pathological signature in Alzheimer's disease and other tauopathies. Brain 135, 807-818 https://doi.org/10.1093/brain/aws013
  39. Luo Y, Ma B, Nussinov R and Wei G (2014) Structural Insight into Tau Protein's Paradox of Intrinsically Disordered Behavior, Self-Acetylation Activity, and Aggregation. J Phys Chem Lett 5, 3026-3031 https://doi.org/10.1021/jz501457f
  40. Santa-Maria I, Hernandez F, Martin CP, Avila J and Moreno FJ (2004) Quinones facilitate the self-assembly of the phosphorylated tubulin binding region of tau into fibrillar polymers. Biochemistry 43, 2888-2897 https://doi.org/10.1021/bi035345j
  41. Perez M, Hernandez F, Lim F, Diaz-Nido J and Avila J (2003) Chronic lithium treatment decreases mutant tau protein aggregation in a transgenic mouse model. J Alzheimers Dis 5, 301-308 https://doi.org/10.3233/JAD-2003-5405
  42. Noble W, Planel E, Zehr C et al (2005) Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. Proc Natl Acad Sci U S A 102, 6990-6995 https://doi.org/10.1073/pnas.0500466102
  43. Avila J (2006) Tau phosphorylation and aggregation in Alzheimer's disease pathology. FEBS Lett 580, 2922-2927 https://doi.org/10.1016/j.febslet.2006.02.067
  44. Kopke E, Tung YC, Shaikh S, Alonso AC, Iqbal K and Grundke-Iqbal I (1993) Microtubule-associated protein tau. Abnormal phosphorylation of a non-paired helical filament pool in Alzheimer disease. J Biol Chem 268, 24374-24384
  45. Kenessey A and Yen SH (1993) The extent of phosphorylation of fetal tau is comparable to that of PHF-tau from Alzheimer paired helical filaments. Brain Res 629, 40-46 https://doi.org/10.1016/0006-8993(93)90478-6
  46. Lee G, Thangavel R, Sharma VM et al (2004) Phosphorylation of tau by fyn: implications for Alzheimer's disease. J Neurosci 24, 2304-2312 https://doi.org/10.1523/JNEUROSCI.4162-03.2004
  47. Braak E, Braak H and Mandelkow EM (1994) A sequence of cytoskeleton changes related to the formation of neurofibrillary tangles and neuropil threads. Acta Neuropathol 87, 554-567 https://doi.org/10.1007/BF00293315
  48. Lucas JJ, Hernandez F, Gomez-Ramos P, Moran MA, Hen R and Avila J (2001) Decreased nuclear beta-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3beta conditional transgenic mice. EMBO J 20, 27-39 https://doi.org/10.1093/emboj/20.1.27
  49. Forlenza OV, Aprahamian I, de Paula VJ and Hajek T (2016) Lithium, a Therapy for AD: Current Evidence from Clinical Trials of Neurodegenerative Disorders. Curr Alzheimer Res 13, 879-886 https://doi.org/10.2174/1567205013666160219112854
  50. King MK, Pardo M, Cheng Y, Downey K, Jope RS and Beurel E (2014) Glycogen synthase kinase-3 inhibitors: Rescuers of cognitive impairments. Pharmacol Ther 141, 1-12 https://doi.org/10.1016/j.pharmthera.2013.07.010
  51. Matsunaga S, Kishi T, Annas P, Basun H, Hampel H and Iwata N (2015) Lithium as a Treatment for Alzheimer's Disease: A Systematic Review and Meta-Analysis. J Alzheimers Dis 48, 403-410 https://doi.org/10.3233/JAD-150437
  52. Yu Y, Run X, Liang Z et al (2009) Developmental regulation of tau phosphorylation, tau kinases, and tau phosphatases. J Neurochem 108, 1480-1494 https://doi.org/10.1111/j.1471-4159.2009.05882.x
  53. Noble W, Hanger DP, Miller CC and Lovestone S (2013) The importance of tau phosphorylation for neurodegenerative diseases. Front Neurol 4, 83
  54. Sontag JM and Sontag E (2014) Protein phosphatase 2A dysfunction in Alzheimer's disease. Front Mol Neurosci 7, 16
  55. Liu F, Grundke-Iqbal I, Iqbal K and Gong CX (2005) Contributions of protein phosphatases PP1, PP2A, PP2B and PP5 to the regulation of tau phosphorylation. Eur J Neurosci 22, 1942-1950 https://doi.org/10.1111/j.1460-9568.2005.04391.x
  56. Gong CX, Shaikh S, Wang JZ, Zaidi T, Grundke-Iqbal I and Iqbal K (1995) Phosphatase activity toward abnormally phosphorylated tau: decrease in Alzheimer disease brain. J Neurochem 65, 732-738
  57. Gong CX, Singh TJ, Grundke-Iqbal I and Iqbal K (1993) Phosphoprotein phosphatase activities in Alzheimer disease brain. J Neurochem 61, 921-927 https://doi.org/10.1111/j.1471-4159.1993.tb03603.x
  58. Choi WH, de Poot SA, Lee JH et al (2016) Open-gate mutants of the mammalian proteasome show enhanced ubiquitin-conjugate degradation. Nat Commun 7, 10963 https://doi.org/10.1038/ncomms10963
  59. Han DH, Na HK, Choi WH et al (2014) Direct cellular delivery of human proteasomes to delay tau aggregation. Nat Commun 5, 5633 https://doi.org/10.1038/ncomms6633
  60. Jiang Y, Lee J, Lee JH et al (2016) The arginylation branch of the N-end rule pathway positively regulates cellular autophagic flux and clearance of proteotoxic proteins. Autophagy 12, 2197-2212 https://doi.org/10.1080/15548627.2016.1222991
  61. Kim JH, Kim E, Choi WH et al (2016) Inhibitory RNA Aptamers of Tau Oligomerization and Their Neuroprotective Roles against Proteotoxic Stress. Mol Pharm 13, 2039-2048 https://doi.org/10.1021/acs.molpharmaceut.6b00165
  62. Karabiyik C, Lee MJ and Rubinsztein DC (2017) Autophagy impairment in Parkinson's disease. Essays Biochem 61, 711-720 https://doi.org/10.1042/EBC20170023
  63. Cohen TJ, Friedmann D, Hwang AW, Marmorstein R and Lee VM (2013) The microtubule-associated tau protein has intrinsic acetyltransferase activity. Nat Struct Mol Biol 20, 756-762 https://doi.org/10.1038/nsmb.2555
  64. Dickey CA, Kamal A, Lundgren K et al (2007) The high-affinity HSP90-CHIP complex recognizes and selectively degrades phosphorylated tau client proteins. J Clin Invest 117, 648-658 https://doi.org/10.1172/JCI29715
  65. Dickey CA, Dunmore J, Lu B et al (2006) HSP induction mediates selective clearance of tau phosphorylated at proline-directed Ser/Thr sites but not KXGS (MARK) sites. FASEB J 20, 753-755 https://doi.org/10.1096/fj.05-5343fje
  66. Liu WK, Ksiezak-Reding H and Yen SH (1991) Abnormal tau proteins from Alzheimer's disease brains. Purification and amino acid analysis. J Biol Chem 266, 21723-21727
  67. David DC, Layfield R, Serpell L, Narain Y, Goedert M and Spillantini MG (2002) Proteasomal degradation of tau protein. J Neurochem 83, 176-185 https://doi.org/10.1046/j.1471-4159.2002.01137.x
  68. Grune T, Botzen D, Engels M et al (2010) Tau protein degradation is catalyzed by the ATP/ubiquitin-independent 20S proteasome under normal cell conditions. Arch Biochem Biophys 500, 181-188 https://doi.org/10.1016/j.abb.2010.05.008
  69. Mori H, Kondo J and Ihara Y (1987) Ubiquitin is a component of paired helical filaments in Alzheimer's disease. Science 235, 1641-1644 https://doi.org/10.1126/science.3029875
  70. Perry G, Friedman R, Shaw G and Chau V (1987) Ubiquitin is detected in neurofibrillary tangles and senile plaque neurites of Alzheimer disease brains. Proc Natl Acad Sci U S A 84, 3033-3036 https://doi.org/10.1073/pnas.84.9.3033
  71. Cripps D, Thomas SN, Jeng Y, Yang F, Davies P and Yang AJ (2006) Alzheimer disease-specific conformation of hyperphosphorylated paired helical filament-Tau is polyubiquitinated through Lys-48, Lys-11, and Lys-6 ubiquitin conjugation. J Biol Chem 281, 10825-10838 https://doi.org/10.1074/jbc.M512786200
  72. Morishima-Kawashima M, Hasegawa M, Takio K, Suzuki M, Titani K and Ihara Y (1993) Ubiquitin is conjugated with amino-terminally processed tau in paired helical filaments. Neuron 10, 1151-1160 https://doi.org/10.1016/0896-6273(93)90063-W
  73. Paine S, Bedford L, Thorpe JR et al (2009) Immunoreactivity to Lys63-linked polyubiquitin is a feature of neurodegeneration. Neurosci Lett 460, 205-208 https://doi.org/10.1016/j.neulet.2009.05.074
  74. Tan JM, Wong ES, Kirkpatrick DS et al (2008) Lysine 63-linked ubiquitination promotes the formation and autophagic clearance of protein inclusions associated with neurodegenerative diseases. Hum Mol Genet 17, 431-439 https://doi.org/10.1093/hmg/ddm320
  75. Tan Z, Sun X, Hou FS et al (2007) Mutant ubiquitin found in Alzheimer's disease causes neuritic beading of mitochondria in association with neuronal degeneration. Cell Death Differ 14, 1721-1732 https://doi.org/10.1038/sj.cdd.4402180
  76. Keck S, Nitsch R, Grune T and Ullrich O (2003) Proteasome inhibition by paired helical filament-tau in brains of patients with Alzheimer's disease. J Neurochem 85, 115-122 https://doi.org/10.1046/j.1471-4159.2003.01642.x
  77. Keller JN, Hanni KB and Markesbery WR (2000) Impaired proteasome function in Alzheimer's disease. J Neurochem 75, 436-439
  78. Lopez Salon M, Morelli L, Castano EM, Soto EF and Pasquini JM (2000) Defective ubiquitination of cerebral proteins in Alzheimer's disease. J Neurosci Res 62, 302-310 https://doi.org/10.1002/1097-4547(20001015)62:2<302::AID-JNR15>3.0.CO;2-L
  79. Cardozo C and Michaud C (2002) Proteasome-mediated degradation of tau proteins occurs independently of the chymotrypsin-like activity by a nonprocessive pathway. Arch Biochem Biophys 408, 103-110 https://doi.org/10.1016/S0003-9861(02)00493-9
  80. Zhang JY, Liu SJ, Li HL and Wang JZ (2005) Microtubule-associated protein tau is a substrate of ATP/Mg(2+)-dependent proteasome protease system. J Neural Transm 112, 547-555 https://doi.org/10.1007/s00702-004-0196-x
  81. de Vrij FM, Fischer DF, van Leeuwen FW and Hol EM (2004) Protein quality control in Alzheimer's disease by the ubiquitin proteasome system. Prog Neurobiol 74, 249-270 https://doi.org/10.1016/j.pneurobio.2004.10.001
  82. Lee MJ, Lee JH and Rubinsztein DC (2013) Tau degradation: the ubiquitin-proteasome system versus the autophagy-lysosome system. Prog Neurobiol 105, 49-59 https://doi.org/10.1016/j.pneurobio.2013.03.001
  83. Petrucelli L, Dickson D, Kehoe K et al (2004) CHIP and Hsp70 regulate tau ubiquitination, degradation and aggregation. Hum Mol Genet 13, 703-714 https://doi.org/10.1093/hmg/ddh083
  84. Babu JR, Geetha T and Wooten MW (2005) Sequestosome 1/p62 shuttles polyubiquitinated tau for proteasomal degradation. J Neurochem 94, 192-203 https://doi.org/10.1111/j.1471-4159.2005.03181.x
  85. Flach K, Ramminger E, Hilbrich I et al (2014) Axotrophin/MARCH7 acts as an E3 ubiquitin ligase and ubiquitinates tau protein in vitro impairing microtubule binding. Biochim Biophys Acta 1842, 1527-1538 https://doi.org/10.1016/j.bbadis.2014.05.029
  86. Shimura H, Schwartz D, Gygi SP and Kosik KS (2004) CHIP-Hsc70 complex ubiquitinates phosphorylated tau and enhances cell survival. J Biol Chem 279, 4869-4876 https://doi.org/10.1074/jbc.M305838200
  87. Hatakeyama S, Matsumoto M, Kamura T et al (2004) U-box protein carboxyl terminus of Hsc70-interacting protein (CHIP) mediates poly-ubiquitylation preferentially on four-repeat Tau and is involved in neurodegeneration of tauopathy. J Neurochem 91, 299-307 https://doi.org/10.1111/j.1471-4159.2004.02713.x
  88. Sahara N, Murayama M, Mizoroki T et al (2005) In vivo evidence of CHIP up-regulation attenuating tau aggregation. J Neurochem 94, 1254-1263 https://doi.org/10.1111/j.1471-4159.2005.03272.x
  89. Joshi V, Amanullah A, Upadhyay A, Mishra R, Kumar A and Mishra A (2016) A Decade of Boon or Burden: What Has the CHIP Ever Done for Cellular Protein Quality Control Mechanism Implicated in Neurodegeneration and Aging? Front Mol Neurosci 9, 93
  90. Gupta R, Lan M, Mojsilovic-Petrovic J et al (2017) The Proline/Arginine Dipeptide from Hexanucleotide Repeat Expanded C9ORF72 Inhibits the Proteasome. eNeuro 4, e0249-16
  91. Shin SK, Kim JH, Lee JH et al (2017) Docosahexaenoic acid-mediated protein aggregates may reduce proteasome activity and delay myotube degradation during muscle atrophy in vitro. Exp Mol Med 49, e287 https://doi.org/10.1038/emm.2016.133
  92. Lee JH, Shin SK, Jiang Y et al (2015) Facilitated Tau Degradation by USP14 Aptamers via Enhanced Proteasome Activity. Sci Rep 5, 10757 https://doi.org/10.1038/srep10757
  93. Wang Y, Garg S, Mandelkow EM and Mandelkow E (2010) Proteolytic processing of tau. Biochem Soc Trans 38, 955-961 https://doi.org/10.1042/BST0380955